Open-label pilot study of combination therapy with rosiglitazone and bexarotene in the treatment of cutaneous T-cell lymphoma.

Sepmeyer JA, Greer JP, Koyama T, Zic JA
J Am Acad Dermatol. 2007 56 (4): 584-7

PMID: 17184879 · DOI:10.1016/j.jaad.2006.10.033

Four patients with stable or progressive cutaneous T-cell lymphoma treated with oral bexarotene received oral rosiglitazone. After 16 weeks of combination therapy, skin score decreased in two patients. Pruritus was alleviated in 3 of 4 patients, whereas quality of life was unchanged. Adverse events included hyperlipidemia, anemia, neutropenia, and lymphopenia.

MeSH Terms (24)

Aged Anticarcinogenic Agents Bexarotene Biopsy, Needle Dose-Response Relationship, Drug Drug Administration Schedule Drug Therapy, Combination Female Follow-Up Studies Humans Immunohistochemistry Lymphoma, T-Cell, Cutaneous Male Maximum Tolerated Dose Middle Aged Neoplasm Staging Pilot Projects Risk Assessment Rosiglitazone Single-Blind Method Survival Analysis Tetrahydronaphthalenes Thiazolidinediones Treatment Outcome

Connections (1)

This publication is referenced by other Labnodes entities: